Osaka U YAP-CTGF Axis Prevents Liver Fibrosis | AcademicJobs
Osaka University uncovers integrin αV-YAP-CTGF axis in LSECs driving fibrosis in congestive hepatopathy, offering new targets to halt portal hypertension and liver cancer progression.
No reviews yet. Be the first to rate Hayato!
Hayato Hikita is an Associate Professor in the Department of Gastroenterology at Osaka University Graduate School of Medicine. He earned his medical degree from Osaka University Faculty of Medicine in 2001 and completed his doctoral program in clinical medicine at the same institution in 2010. His career at Osaka University includes roles as Project Assistant Professor starting in 2012, Assistant Professor in 2015, Lecturer in 2017, and promotion to Associate Professor in 2026. Prior positions encompass residency at Osaka University Hospital and National Osaka Minami Hospital.
Hikita specializes in chronic and acute hepatitis, including viral liver disease, fatty liver disease, autoimmune hepatobiliary disease, and fulminant hepatitis, as well as hepatobiliary pancreatic cancer. His research focuses on clarifying the molecular mechanisms of hepatobiliary and pancreatic diseases and developing new treatments and biomarkers. He holds numerous professional certifications and leadership roles, including councilor positions in the Japanese Society of Internal Medicine, Japanese Society of Gastroenterology, Japan Society of Hepatology, and Japanese Society of Gastrointestinal Endoscopy, along with specialist certifications and fellowship in the American Association for the Study of Liver Diseases (FAASLD). He has contributed to multiple research publications in the field of gastroenterology and hepatology.
Osaka University uncovers integrin αV-YAP-CTGF axis in LSECs driving fibrosis in congestive hepatopathy, offering new targets to halt portal hypertension and liver cancer progression.